ForecastQ
PortfoliosScreenerAbout
Screener > NAMS

NAMS

NewAmsterdam Pharma Company N.V.
  • Healthcare
  • Biotechnology
  • $2.67B market cap
Forecast run · Sep 14, 2026Upside rank 808 of 3,136

Model Signal

ForecastQ Daily Probabilities
48.8%
36.7%
27.4%

Analyst Consensus

Recommendation2.10/5 Buy
Last price$22.80
Price target$51.33
Implied move+125.1%
Analysts10

ForecastQ Portfolios

NAMS is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

ForecastQ

Quantitative stocks signals powered by AI

Portfolios·Screener·About

The information provided is for educational purposes only and should not be considered financial advice. Past performance is not indicative of future results. ForecastQ is a research platform, a living documentation of an engineering experiment. We are not financial advisors.

© ForecastQ. All rights reserved.